Antigen peptides
Tumor-associated antigens (TAAs) act as target peptides to induce cytotoxic T lymphocyte (CTL) responses for the development of cancer vaccines, a promising approach for cancer immunotherapy.
Tumor-associated antigens are selected based on their, immunogenicity, role in oncogenicity, number of antigenic epitopes and their expression level in antigen-positive cancer cells1.
Receptors of CD8+ T cells usually recognize antigenic peptides presented in association with MHC class I molecules. Peptides displayed on the HLA-A*0201 molecules are the most frequently used since this HLA allele (HLA-A group, MHC class I) is expressed by 45% of the human population and the peptide binding motifs are well-charaterized1.
To validate the efficacy of a tumor-associated antigen as a T-cell epitope, CD8+ T cells are usually induced in vitro using peptide-pulsed dendritic cells (DCs), generated from peripheral blood mononuclear cells (PBMCs), as antigen-presenting cells (APCs). Upon primary in vitro immunization, peptide-responding T cells are analyzed for their capacity to recognize tumor cell lines expressing the candidate tumor-associated antigen and to trigger an antigen-specific and HLA-A*02-restricted cytolytic activity against the target tumor cells. This approach is nammed reverse immunology. It has been successfully used to identify several antigenic peptides that are recognized by CD4+ or CD8+ T lymphocytes.
Tumour-associated antigens that have the potential to elicit immune responses are classified into different categories2 :
- Antigens of high tumoural specificity
Antigens derived from oncogenic viruses
Antigens encoded by mutated genes
Antigens encoded by cancer-germline genes - Antigens of low tumoural specificity
Tissue/Lineage-restricted differentiation antigens
Antigens derived from overexpressed proteins
Name | Description | Catalog # | More details |
---|---|---|---|
Melan-A / MART1 (26-35) peptide | Tumor-associated antigen peptide | SB026 | Click here |
MUC1 (12-20) peptide | Tumor-associated antigen peptide | SB027 | Click here |
OVA 257-264 | Tumor-associated antigen peptide | SB031 | Click here |
TRP-2 Peptide (180-188) | Tumor-associated antigen peptide | SB033 | Click here |
PADRE peptide | Tumor-associated antigen peptide | SB054 | Click here |
A*02:01/Human Survivin (96-104) | Tumor-associated antigen peptide | SB055 | Click here |
FluM1 (58-66) | Tumor-associated antigen peptide | SB056 | Click here |
HIV-1 p17 Gag (77-85) | Tumor-associated antigen peptide | SB057 | Click here |
HCV NS5B (2594-2602) | Tumor-associated antigen peptide | SB058 | Click here |
Ova (323-339) | Tumor-associated antigen peptide | SB059 | Click here |
CD20 (188-196) | Tumor-associated antigen peptide | SB060 | Click here |
CMV pp65 (120-129) | Tumor-associated antigen peptide | SB061 | Click here |
NY-ESO-1 (157-165) | Tumor-associated antigen peptide | SB062 | Click here |
NY-ESO-1 (123-137) DRB1*04:01 | Tumor-associated antigen peptide | SB063 | Click here |
MAGE-A1 (278-286) | Tumor-associated antigen peptide | SB064 | Click here |
HER-2/neu (85-94) | Tumor-associated antigen peptide | SB065 | Click here |
A*02:01/Human Survivin (LMLGEFLKL) | Tumor-associated antigen peptide | SB066 | Click here |
MAGE-A p248V9 | Tumor-associated antigen peptide | SB067 | Click here |
Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) | Tumor-associated antigen peptide | SB068 | Click here |
EBV BMLF1 (280-288) | Tumor-associated antigen peptide | SB069 | Click here |
MAGE-A2 (157-166) | Tumor-associated antigen peptide | SB070 | Click here |
CMV pp65 (113-121) | Tumor-associated antigen peptide | SB071 | Click here |
OVA 257-264 scrambled | Tumor-associated antigen peptide | SB073 | Click here |
Biotin-FluM1 (58-66) | Tumor-associated antigen peptide | SB074 | Click here |
Biotin-Ova (323-339) | Tumor-associated antigen peptide | SB075 | Click here |
Biotin-NY-ESO-1 (157-165) | Tumor-associated antigen peptide | SB076 | Click here |
Biotin-MAGE-A1 (278-286) | Tumor-associated antigen peptide | SB077 | Click here |
Biotin-MAGE-A2 (157-166) | Tumor-associated antigen peptide | SB078 | Click here |
NY-ESO-1 (157-165) scrambled | Tumor-associated antigen peptide | SB079 | Click here |
MAGE-A p248V9 scrambled | Tumor-associated antigen peptide | SB080 | Click here |
Melan-A/MART 1 (26-35) scrambled | Tumor-associated antigen peptide | SB081 | Click here |
MAGE-A2 (157-166) scrambled | Tumor-associated antigen peptide | SB082 | Click here |
MAGE-A1 (278-286) scrambled | Tumor-associated antigen peptide | SB083 | Click here |
PADRE scrambled | Tumor-associated antigen peptide | SB084 | Click here |